Acouphénia aims to reproduce the precise sound of each patient’s tinnitus, then adjust hearing aids to make that perception less intrusive. The family business is now developing a dedicated device that it plans to manufacture in France, alongside a phone-based preliminary test that directs patients to its network of specialized hearing care professionals.
The challenge is to characterize a sound that, in about 95% of cases, only the patient can hear, explains Xavier Carriou, a hearing aid specialist and Acouphénia’s founder. Tinnitus is a symptom, not a disease, he emphasizes. Estimates he cites put the share of the world’s population living with permanent tinnitus at 14%, with nearly 3% experiencing disabling forms. The consequences can include sleep disruption, difficulty concentrating, anxiety and social isolation.
Faced with these subjective perceptions, patients are still often told to learn to live with them. Carriou advocates a more precise approach: establish what the person hears before trying to reduce its impact.
His work began with his mother’s experience of tinnitus. Over his career, he gradually identified five broad sound categories: whistling, hissing, buzzing, humming and pure tones. A patent application covering their characterization was filed in 2013. Software was subsequently developed to reproduce the perceived sound with the patient’s participation.
Called Tinnitometer V3, the software helps practitioners analyze tinnitus and select appropriate settings. Louis Carriou, the founder’s son and director of research and development, draws a distinction with a conventional audiometer: that instrument measures hearing, while their software seeks to characterize tinnitus in detail, with what he describes as substantially greater precision at the relevant frequencies.
Once the sound has been identified, an expert system helps the hearing aid specialist select the device’s channels and amplification levels. The aim is to enrich the patient’s acoustic environment at the relevant frequency so that external sounds make the tinnitus less noticeable.
Xavier Carriou says the company’s observations show an immediate benefit for 94% of treated patients who meet its criteria. He explicitly distinguishes relief from a cure, however: the effect depends in part on wearing the device, and the tinnitus may become noticeable again when it is removed.
To spread its method, Acouphénia chose to build a network rather than sell only its software. A capable tool is not enough without training in its use, Louis Carriou explains. The business therefore combines technology with professional training and support.
More than 200 hearing aid specialists joined the network in less than two years, including more than 100 in France. Acouphénia also operates in several European countries, Africa and the Americas. Its twin objectives are to help patients find specialized practitioners and to help hearing aid professionals develop specific expertise. It also wants to better inform primary care doctors and ear, nose and throat specialists, often patients’ first point of contact.
The company’s new website offers a tinnitus test that can be used on a phone with earphones or headphones. Users can progressively refine the characteristics of the sound they perceive, then find a nearby Acouphénia practitioner. This preliminary exercise does not replace an in-depth assessment in a testing booth. Louis Carriou says it is intended to simplify the care pathway and give specialists more time to support patients and identify a suitable solution.
Meanwhile, the business is building a 600-square-meter manufacturing facility in Anjou to house research and future production. It aims to develop a device specifically for tinnitus that is more affordable than conventional hearing aids.
Xavier Carriou places the project within a broader commitment to independence, innovation and keeping expertise in France. The family’s ambition is to change tinnitus care over the long term. The dedicated device is still to come; the current method already pursues a specific goal: reducing tinnitus’s prominence in what a patient hears, without promising to make it disappear.


